ループス治療薬の世界市場レポート 2025年

ループス治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は8.7％で、41億6,000万米ドルに成長します。予測期間の成長は、医薬品承認・上市の増加、新興市場、疾患認識・診断の改善、啓発活動の高まり、免疫抑制製品などに起因します。予測期間の主な動向には、キメラ抗原受容体T細胞（CAR-T）療法、ループスに対する低分子治療薬、ループスに対するCAR-NK療法、全身性エリテマトーデス（SLE）におけるヒト形質細胞様樹状細胞活性の複合阻害、尿プロテオミクスなどがあります。

ループス治療薬市場の成長は、研究開発活動の活発化によって促進されると予想されます。このような活動には、さまざまな分野にわたる知識、技術、製品開発の向上を目的とした体系的な調査や実験が含まれます。研究開発活動は、イノベーション、技術進歩、新たな課題への対応、ヘルスケア成果の改善、科学技術のブレークスルーによる経済成長の促進などの必要性によって推進されています。研究開発の努力は、新しい治療法の発見、既存の治療法の強化、疾患の根本的なメカニズムの理解を深めることにより、ループス治療薬の進展に貢献します。例えば、米国議会調査局が2023年3月に発表した報告書によると、国立衛生研究所が2023年に受け取った研究開発費は491億8,300万米ドルで、2021年の429億4,100万米ドルから増加しています。この資金提供は、ループス治療薬に関連する取り組みを含む医学研究の推進へのコミットメントが高まっていることを強調するものであり、市場成長を促進するものです。

ループス治療薬市場では、主要企業が診断精度と治療効果を向上させるため、予測人工知能を組み込んだ先進的な血液検査の開発に注力しています。これらの血液検査は、AIアルゴリズムを活用して血液サンプル中のバイオマーカーを分析し、病気の転帰や治療効果をより正確に予測します。例えば、米国のプレシジョン・メディシン企業であるAMPEL BioSolutions LLCは、2024年3月にLuGENE血液検査を開始しました。この革新的な検査は、予測AIによる遺伝子発現解析を通じて、ループスの再燃を予測し、薬剤ターゲットを特定します。この検査は、炎症や免疫機能障害に関連する遺伝子発現のリアルタイムの異常に基づいて個別化された治療選択肢を提供することで、ループス管理に革命を起こすことを目指しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ループス治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のループス治療薬市場：成長率分析
• 世界のループス治療薬市場の実績：規模と成長, 2019-2024
• 世界のループス治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界ループス治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のループス治療薬市場：疾患タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 全身性エリテマトーデス（SLE）
• 皮膚エリテマトーデス
• 薬剤誘発性ループスエリテマトーデス
• 新生児ループス
• 世界のループス治療薬市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非ステロイド性抗炎症薬（NSAID）
• 生物学的製剤
• 抗マラリア薬
• コルチコステロイド
• その他の治療の種類
• 世界のループス治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 皮下
• 静脈内
• その他の投与経路
• 世界のループス治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診療所
• 診断検査室
• その他のエンドユーザー
• 世界のループス治療薬市場全身性エリテマトーデス（SLE）の病型別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 軽度のSLE
• 中等度のSLE
• 重度のSLE
• 世界のループス治療薬市場皮膚エリテマトーデスの病型別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 急性皮膚ループス
• 亜急性皮膚ループス
• 慢性皮膚ループス（円板状ループスを含む）
• 世界のループス治療薬市場薬剤誘発性ループスエリテマトーデスの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬剤誘発性ループスを引き起こすことが知られている薬剤
• ヒドララジン
• プロカインアミド
• イソニアジド
• 世界のループス治療薬市場新生児ループスのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 心臓関連新生児ループス
• 皮膚関連新生児ループス

第7章 地域別・国別分析

• 世界のループス治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のループス治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ループス治療薬市場：競合情勢
• ループス治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca PLC
• Novartis AG
• Roche Holdings Inc.
• GlaxoSmithKline plc
• Eli Lilly and Company
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Bausch Health Companies Inc.
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma
• Dr. Reddy's Laboratories Ltd.
• Hikma Pharmaceuticals PLC
• Amneal Pharmaceuticals LLC
• Lupin Ltd
• Zydus Lifesciences Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ループス治療薬市場2029：新たな機会を提供する国
• ループス治療薬市場2029：新たな機会を提供するセグメント
• ループス治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Lupus therapeutics encompass treatments and medications specifically designed to manage and alleviate the symptoms of lupus, an autoimmune disease in which the body's immune system attacks its own tissues, causing inflammation and damage in various organs. These treatments aim to reduce inflammation, suppress the overactive immune response, and improve patients' quality of life.

The primary types of lupus therapeutics include systemic lupus erythematosus, cutaneous lupus erythematosus, drug-induced lupus erythematosus, neonatal lupus, and others. Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects various organs and tissues, characterized by inflammation and damage to these organs. Treatments for lupus include non-steroidal anti-inflammatory drugs (NSAIDs), biologics, antimalarial drugs, corticosteroids, and others. These drugs can be administered orally, subcutaneously, intravenously, and by other methods, and are used in various settings, such as hospitals and clinics, diagnostic laboratories, and others.

The lupus therapeutics research report is one of a series of new reports from The Business Research Company that provides lupus therapeutics market statistics, including the lupus therapeutics industry's global market size, regional shares, competitors with a lupus therapeutics market share, detailed lupus therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the lupus therapeutics industry. This lupus therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The lupus therapeutics market size has grown strongly in recent years. It will grow from $2.74 billion in 2024 to $2.99 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to the increased prevalence of lupus, increased investment in healthcare infrastructure, high disposable income, high demand for effective therapies, and rising geriatric population.

The lupus therapeutics market size is expected to see strong growth in the next few years. It will grow to $4.16 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to rising drug approvals and launches, emerging markets, improvements in disease awareness and diagnosis, rising awareness initiatives, and immunosuppressive products. Major trends in the forecast period include chimeric antigen receptor T-cell (CAR-T) therapy, small molecule therapeutics for lupus, CAR-NK therapy for lupus, combined inhibition of human plasmacytoid dendritic cell activity during systemic lupus, erythematosus (SLE), urine proteomics.

The growth of the lupus therapeutics market is expected to be propelled by increasing research and development activities. These activities encompass systematic investigation and experimentation aimed at advancing knowledge, technology, or product development across various fields. They are driven by the need for innovation, technological advancements, addressing emerging challenges, improving healthcare outcomes, and fostering economic growth through scientific and technological breakthroughs. Research and development efforts contribute to advancing lupus therapeutics by discovering new treatments, enhancing existing therapies, and deepening understanding of the disease's underlying mechanisms. For instance, a March 2023 report from the Congressional Research Service highlighted that the national institutes of health received $49.183 billion in 2023 for research and development activities, marking an increase from $42.941 billion allocated in 2021. This funding underscores the growing commitment to advancing medical research, including efforts related to lupus therapeutics, thereby driving market growth.

In the lupus therapeutics market, major companies are focused on developing advanced blood tests incorporating predictive artificial intelligence to improve diagnostic accuracy and treatment efficacy. These blood tests utilize AI algorithms to analyze biomarkers in blood samples, predicting disease outcomes or treatment responses more accurately. For example, AMPEL BioSolutions LLC, a US-based precision medicine company, launched the LuGENE blood test in March 2024. This innovative test predicts lupus flares and identifies drug targets through gene expression analysis with predictive AI. It aims to revolutionize lupus management by offering personalized treatment options based on real-time abnormalities in gene expression linked to inflammation and immune dysfunction.

In April 2024, Takeda Pharmaceutical Company Limited, a Japan-based biotechnology firm, acquired Nimbus Therapeutics' TYK2 program from Nimbus Lakshmi Inc. This strategic acquisition enhances Takeda's position in the immunology market and expands its portfolio of treatments for immune-mediated diseases, including lupus. Nimbus Lakshmi Inc., based in the US, specializes in developing drugs for various conditions, including lupus and psoriasis.

Major companies operating in the lupus therapeutics market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sanofi SA, AstraZeneca PLC, Novartis AG, Roche Holdings Inc., GlaxoSmithKline plc, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Lupin Ltd, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited

North America was the largest region in the lupus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lupus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the lupus therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lupus therapeutics market consists of revenues earned by entities by providing services such as autoantibody testing, anti-phospholipid antibody testing, and rheumatoid factor testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The lupus therapeutics market also includes sales of calcineurin inhibitors, immunosuppressants, anticoagulants, and antimalarial drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lupus Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lupus therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for lupus therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The lupus therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease Type: Systemic Lupus Erythematosus (SLE); Cutaneous Lupus Erythematosus; Drug-Induced Lupus Erythematosus; Neonatal Lupus
• 2) By Treatment Type: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); Biologics; Antimalarial Drugs; Corticosteroids; Other Treatment Types
• 3) By Route Of Administration: Oral; Subcutaneous; Intravenous; Other Routes Of Administration
• 4) By End User: Hospitals And Clinics; Diagnostic Laboratories; Other End Users
• Subsegments:
• 1) By Systemic Lupus Erythematosus (SLE): Mild SLE; Moderate SLE; Severe SLE
• 2) By Cutaneous Lupus Erythematosus: Acute Cutaneous Lupus; Subacute Cutaneous Lupus; Chronic Cutaneous Lupus (Including Discoid Lupus)
• 3) By Drug-Induced Lupus Erythematosus: Medications Known To Cause Drug-Induced Lupus; Hydralazine; Procainamide; Isoniazid
• 4) By Neonatal Lupus: Heart-Related Neonatal Lupus; Skin-Related Neonatal Lupus
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; AbbVie Inc.; Sanofi SA
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Lupus Therapeutics Market Characteristics

3. Lupus Therapeutics Market Trends And Strategies

4. Lupus Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Lupus Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Lupus Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Lupus Therapeutics Market Growth Rate Analysis
• 5.4. Global Lupus Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Lupus Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Lupus Therapeutics Total Addressable Market (TAM)

6. Lupus Therapeutics Market Segmentation

• 6.1. Global Lupus Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Systemic Lupus Erythematosus (SLE)
• Cutaneous Lupus Erythematosus
• Drug-Induced Lupus Erythematosus
• Neonatal Lupus
• 6.2. Global Lupus Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Biologics
• Antimalarial Drugs
• Corticosteroids
• Other Treatment Types
• 6.3. Global Lupus Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Subcutaneous
• Intravenous
• Other Routes Of Administration
• 6.4. Global Lupus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Diagnostic Laboratories
• Other End Users
• 6.5. Global Lupus Therapeutics Market, Sub-Segmentation Of Systemic Lupus Erythematosus (SLE), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mild SLE
• Moderate SLE
• Severe SLE
• 6.6. Global Lupus Therapeutics Market, Sub-Segmentation Of Cutaneous Lupus Erythematosus, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Cutaneous Lupus
• Subacute Cutaneous Lupus
• Chronic Cutaneous Lupus (Including Discoid Lupus)
• 6.7. Global Lupus Therapeutics Market, Sub-Segmentation Of Drug-Induced Lupus Erythematosus, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medications Known To Cause Drug-Induced Lupus
• Hydralazine
• Procainamide
• Isoniazid
• 6.8. Global Lupus Therapeutics Market, Sub-Segmentation Of Neonatal Lupus, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Heart-Related Neonatal Lupus
• Skin-Related Neonatal Lupus

7. Lupus Therapeutics Market Regional And Country Analysis

• 7.1. Global Lupus Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Lupus Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Lupus Therapeutics Market

• 8.1. Asia-Pacific Lupus Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Lupus Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Lupus Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Lupus Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Lupus Therapeutics Market

• 9.1. China Lupus Therapeutics Market Overview
• 9.2. China Lupus Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Lupus Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Lupus Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Lupus Therapeutics Market

• 10.1. India Lupus Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Lupus Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Lupus Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Lupus Therapeutics Market

• 11.1. Japan Lupus Therapeutics Market Overview
• 11.2. Japan Lupus Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Lupus Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Lupus Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Lupus Therapeutics Market

• 12.1. Australia Lupus Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Lupus Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Lupus Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Lupus Therapeutics Market

• 13.1. Indonesia Lupus Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Lupus Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Lupus Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Lupus Therapeutics Market

• 14.1. South Korea Lupus Therapeutics Market Overview
• 14.2. South Korea Lupus Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Lupus Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Lupus Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Lupus Therapeutics Market

• 15.1. Western Europe Lupus Therapeutics Market Overview
• 15.2. Western Europe Lupus Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Lupus Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Lupus Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Lupus Therapeutics Market

• 16.1. UK Lupus Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Lupus Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Lupus Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Lupus Therapeutics Market

• 17.1. Germany Lupus Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Lupus Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Lupus Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Lupus Therapeutics Market

• 18.1. France Lupus Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Lupus Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Lupus Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Lupus Therapeutics Market

• 19.1. Italy Lupus Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Lupus Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Lupus Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Lupus Therapeutics Market

• 20.1. Spain Lupus Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Lupus Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Lupus Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Lupus Therapeutics Market

• 21.1. Eastern Europe Lupus Therapeutics Market Overview
• 21.2. Eastern Europe Lupus Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Lupus Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Lupus Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Lupus Therapeutics Market

• 22.1. Russia Lupus Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Lupus Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Lupus Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Lupus Therapeutics Market

• 23.1. North America Lupus Therapeutics Market Overview
• 23.2. North America Lupus Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Lupus Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Lupus Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Lupus Therapeutics Market

• 24.1. USA Lupus Therapeutics Market Overview
• 24.2. USA Lupus Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Lupus Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Lupus Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Lupus Therapeutics Market

• 25.1. Canada Lupus Therapeutics Market Overview
• 25.2. Canada Lupus Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Lupus Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Lupus Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Lupus Therapeutics Market

• 26.1. South America Lupus Therapeutics Market Overview
• 26.2. South America Lupus Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Lupus Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Lupus Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Lupus Therapeutics Market

• 27.1. Brazil Lupus Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Lupus Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Lupus Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Lupus Therapeutics Market

• 28.1. Middle East Lupus Therapeutics Market Overview
• 28.2. Middle East Lupus Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Lupus Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Lupus Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Lupus Therapeutics Market

• 29.1. Africa Lupus Therapeutics Market Overview
• 29.2. Africa Lupus Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Lupus Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Lupus Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Lupus Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Lupus Therapeutics Market Competitive Landscape
• 30.2. Lupus Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

31. Lupus Therapeutics Market Other Major And Innovative Companies

• 31.1. AstraZeneca PLC
• 31.2. Novartis AG
• 31.3. Roche Holdings Inc.
• 31.4. GlaxoSmithKline plc
• 31.5. Eli Lilly and Company
• 31.6. Viatris Inc.
• 31.7. Teva Pharmaceutical Industries Ltd.
• 31.8. Bausch Health Companies Inc.
• 31.9. Sun Pharmaceutical Industries Ltd.
• 31.10. Aurobindo Pharma
• 31.11. Dr. Reddy's Laboratories Ltd.
• 31.12. Hikma Pharmaceuticals PLC
• 31.13. Amneal Pharmaceuticals LLC
• 31.14. Lupin Ltd
• 31.15. Zydus Lifesciences Limited

32. Global Lupus Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Lupus Therapeutics Market

34. Recent Developments In The Lupus Therapeutics Market

35. Lupus Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Lupus Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Lupus Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Lupus Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer